WallStreetZenWallStreetZen

NYSE: LLY
Eli Lilly & Co Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

LLY past earnings growth

How has LLY's earnings growth performed historically?
Company
8.08%
Industry
19.47%
Market
117.28%
LLY's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
LLY's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
LLY's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

LLY past revenue growth

How has LLY's revenue growth performed historically?
Company
29.76%
Industry
8.92%
Market
14.94%
LLY's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
LLY's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
LLY's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

LLY earnings and revenue history

Current Revenue
$35.9B
Current Earnings
$6.1B
Current Profit Margin
17.1%
LLY's has not demonstrated consistent... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance

LLY Return on Equity

Current Company
53.5%
Current Industry
34.9%
Current Market
28.2%
LLY's Return on Equity (53.5%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when LLY announces earnings.

LLY Return on Assets

Current Company
10.2%
Current Industry
8.2%
LLY is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

LLY Return on Capital Employed

Current Company
16.67%
Current Industry
14.4%
LLY's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

LLY vs General Drug Manufacturer Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
LLY$35.93B$9.13B$6.14B+10.69%+1.57%
JNJ$81.80B$49.47B$38.48B+0.05%+22.73%
MRK$61.40B$8.97B$2.31B+7.35%-22.24%
ABBV$54.40B$17.85B$5.99B+10.75%-1.20%
AZN$47.61B$14.25B$6.33B+16.27%+16.57%
View Top General Drug Manufacturer Stocks

Eli Lilly & Co Earnings & Revenue FAQ

What were LLY's earnings last quarter?

On Invalid Date, Eli Lilly & Co (NYSE: LLY) reported Q1 2024 earnings per share (EPS) of $2.49, up 67.11% year over year. Total Eli Lilly & Co earnings for the quarter were $2.24 billion. In the same quarter last year, Eli Lilly & Co's earnings per share (EPS) was $1.49.

If you're new to stock investing, here's how to buy Eli Lilly & Co stock.

What was LLY's earnings growth in the past year?

As of Q2 2024, Eli Lilly & Co's earnings has grown 8.08% year over year. This is 11.39 percentage points lower than the US Drug Manufacturers - General industry earnings growth rate of 19.47%. Eli Lilly & Co's earnings in the past year totalled $6.14 billion.

What was LLY's revenue last quarter?

On Invalid Date, Eli Lilly & Co (NYSE: LLY) reported Q1 2024 revenue of $8.77 billion up 25.98% year over year. In the same quarter last year, Eli Lilly & Co's revenue was $6.96 billion.

What was LLY's revenue growth in the past year?

As of Q2 2024, Eli Lilly & Co's revenue has grown 29.76% year over year. This is 20.84 percentage points higher than the US Drug Manufacturers - General industry revenue growth rate of 8.92%. Eli Lilly & Co's revenue in the past year totalled $35.93 billion.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.